Abstract
We are developing agents for the real-time guidance of surgical procedures directed at tumors, in this case ovarian cancer. Folate receptor (FR) is overexpressed in certain cancers, particularly ovarian cancer. We have developed a type-II folate receptor (FR) targeting moiety, and this agent was previously developed into an injectable radiopharmaceutical imaging agent. As this agent is a small molecule, it rapidly equilibrates in tissues, with tumor:blood ratios of 400:1 as the agent is renally excreted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
